Amgen (AMGN) Repatha Meets Endpoints in Phase III Study

Amgen Inc AMGN announced positive top line results from a phase III study evaluating the effect of its cholesterol lowering medication Repatha evolocumab in patients with coronary artery disease CAD Repatha a PCSK9 inhibitor is approved for use in addition to diet and